ANEBULO PHARMACEUTICALS, INC. Stock-Based Compensation
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Stock-Based Compensation of $198.53 thousand for the 3-month period ending 2025-12-31, per its 10-Q filed 2026-02-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-02-12
- ANEBULO PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $198.53K, a 64.82% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $237.64K, a 17.17% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-06-30 was $340.30K, a 92.06% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-03-31 was $300.00K, a 50.00% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $1.45M, a 90.65% increase from fiscal 2024.
- ANEBULO PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $758.88K, a 14.22% decline from fiscal 2023.
- ANEBULO PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $884.72K, a 84.06% increase from fiscal 2022.
- ANEBULO PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $480.66K, a 140.39% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $198.53K 10-Q · filed 2026-02-12 | $436.17K 10-Q · filed 2026-02-12 | $776.48K derived: sum of 3 quarters · filed 2026-02-12 | $1.08M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2025-09-30 | $237.64K 10-Q · filed 2025-11-13 | $577.95K derived: sum of 2 quarters · filed 2025-11-13 | $877.95K derived: sum of 3 quarters · filed 2025-11-13 | $1.44M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2025-06-30 | $340.30K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $640.30K derived: sum of 2 quarters · filed 2025-09-29 | $1.20M derived: sum of 3 quarters · filed 2026-02-12 | $1.45M 10-K · filed 2025-09-29 | |
| 2025-03-31 | $300.00K 10-Q · filed 2025-05-13 | $864.33K derived: sum of 2 quarters · filed 2026-02-12 | $1.11M 10-Q · filed 2025-05-13 | $1.33M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-12-31 | $564.33K 10-Q · filed 2026-02-12 | $600.00K 10-Q · filed 2025-02-14 | $851.25K 10-Q · filed 2026-02-12 | $1.03M derived: sum of 3 quarters · filed 2026-02-12 | $1.23M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | $286.92K 10-Q · filed 2025-11-13 | $464.11K derived: sum of 2 quarters · filed 2025-11-13 | $664.11K derived: sum of 3 quarters · filed 2025-11-13 | $864.11K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $177.19K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $377.19K derived: sum of 2 quarters · filed 2025-09-29 | $577.19K derived: sum of 3 quarters · filed 2025-09-29 | $758.88K 10-K · filed 2025-09-29 | |
| 2024-03-31 | $200.00K 10-Q · filed 2025-05-13 | $400.00K derived: sum of 2 quarters · filed 2025-05-13 | $581.70K 10-Q · filed 2025-05-13 | $834.36K derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $200.00K 10-Q · filed 2025-02-14 | $430.06K 10-Q · filed 2025-02-14 | $634.36K derived: sum of 3 quarters · filed 2025-02-14 | $834.36K derived: sum of 4 quarters · filed 2025-02-14 | |
| 2023-09-30 | $210.80K 10-Q · filed 2024-11-13 | $434.36K derived: sum of 2 quarters · filed 2024-11-13 | $634.36K derived: sum of 3 quarters · filed 2024-11-13 | $834.36K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $223.56K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-25 | $423.56K derived: sum of 2 quarters · filed 2024-09-25 | $623.57K derived: sum of 3 quarters · filed 2024-09-25 | $884.72K 10-K · filed 2024-09-25 | |
| 2023-03-31 | $200.00K 10-Q · filed 2024-05-15 | $223.64K 10-Q · filed 2023-05-11 | $400.00K derived: sum of 2 quarters · filed 2024-05-15 | $661.16K 10-Q · filed 2024-05-15 | $838.85K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $200.00K 10-Q · filed 2024-02-13 | $225.62K 10-Q · filed 2023-02-10 | $437.52K 10-Q · filed 2024-02-13 | $638.85K derived: sum of 3 quarters · filed 2024-02-13 | $764.11K derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | $211.90K 10-Q · filed 2023-11-14 | $438.85K derived: sum of 2 quarters · filed 2023-11-14 | $564.11K derived: sum of 3 quarters · filed 2023-11-14 | $658.39K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $226.95K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-22 | $352.21K derived: sum of 2 quarters · filed 2023-09-22 | $446.49K derived: sum of 3 quarters · filed 2023-09-22 | $480.66K 10-K · filed 2023-09-22 | |
| 2022-03-31 | $125.25K 10-Q · filed 2023-05-11 | $219.54K derived: sum of 2 quarters · filed 2023-05-11 | $253.71K 10-Q · filed 2023-05-11 | $369.15K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $94.28K 10-Q · filed 2023-02-10 | $128.46K 10-Q · filed 2023-02-10 | $243.89K derived: sum of 3 quarters · filed 2023-02-10 | $291.30K derived: sum of 4 quarters · filed 2023-02-10 | |
| 2021-09-30 | $34.17K 10-Q · filed 2022-11-10 | $149.61K derived: sum of 2 quarters · filed 2022-11-10 | $197.02K derived: sum of 3 quarters · filed 2022-11-10 | $217.71K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $115.44K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-09 | $162.84K derived: sum of 2 quarters · filed 2022-09-09 | $183.54K derived: sum of 3 quarters · filed 2022-09-09 | $199.95K 10-K · filed 2022-09-09 | |
| 2021-03-31 | $47.41K 10-Q · filed 2022-05-11 | $68.10K derived: sum of 2 quarters · filed 2022-05-11 | $84.51K 10-Q · filed 2022-05-11 | ||
| 2020-12-31 | $20.69K 10-Q · filed 2022-02-11 | $37.10K 10-Q · filed 2022-02-11 | |||
| 2020-09-30 | $16.41K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |